JP6126078B2 - ４−アルカノイルアミノ−３−ピラゾロン誘導体 - Google Patents

４−アルカノイルアミノ−３−ピラゾロン誘導体 Download PDF

Info

Publication number
JP6126078B2
JP6126078B2 JP2014508119A JP2014508119A JP6126078B2 JP 6126078 B2 JP6126078 B2 JP 6126078B2 JP 2014508119 A JP2014508119 A JP 2014508119A JP 2014508119 A JP2014508119 A JP 2014508119A JP 6126078 B2 JP6126078 B2 JP 6126078B2
Authority
JP
Japan
Prior art keywords
group
dihydro
oxo
pyrazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014508119A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013147215A1 (ja
Inventor
坂本　篤信
篤信 坂本
田中　直樹
直樹 田中
福田　剛
剛 福田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2013147215A1 publication Critical patent/JPWO2013147215A1/ja
Application granted granted Critical
Publication of JP6126078B2 publication Critical patent/JP6126078B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014508119A 2012-03-30 2013-03-29 ４−アルカノイルアミノ−３−ピラゾロン誘導体 Active JP6126078B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012079858 2012-03-30
JP2012079858 2012-03-30
PCT/JP2013/059656 WO2013147215A1 (ja) 2012-03-30 2013-03-29 ４－アルカノイルアミノ－３－ピラゾロン誘導体

Publications (2)

Publication Number Publication Date
JPWO2013147215A1 JPWO2013147215A1 (ja) 2015-12-14
JP6126078B2 true JP6126078B2 (ja) 2017-05-10

Family

ID=49260456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014508119A Active JP6126078B2 (ja) 2012-03-30 2013-03-29 ４−アルカノイルアミノ−３−ピラゾロン誘導体

Country Status (11)

Country Link
US (1) US9212170B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2832733B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6126078B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20140138208A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104321318A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2869130A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2699404T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1204621A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN01988A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW201400470A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013147215A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物
CN112375072B (zh) * 2020-09-28 2021-05-28 上海长征富民金山制药有限公司 吡唑啉酮衍生物、注射剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
BRPI0911393A2 (pt) * 2008-04-22 2015-12-29 Daiichi Sankyo Co Ltd composto de 5-hidroxipirimidina-4-carboxamida
SI2382215T1 (sl) 2008-12-29 2020-06-30 Sanofi Derivati 2-piridin-2-il-pirazol-3(2H)-ona, njihova priprava in njihova terapevtska uporaba
BRPI0924060A8 (pt) 2008-12-29 2015-09-29 Sanofi Sa derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif
JP2011088840A (ja) * 2009-10-21 2011-05-06 Daiichi Sankyo Co Ltd ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物
JP2011105708A (ja) * 2009-10-21 2011-06-02 Daiichi Sankyo Co Ltd ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物

Also Published As

Publication number Publication date
HK1204621A1 (en) 2015-11-27
US20150011552A1 (en) 2015-01-08
EP2832733A4 (en) 2015-09-30
TW201400470A (zh) 2014-01-01
IN2014MN01988A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-10
KR20140138208A (ko) 2014-12-03
CN104321318A (zh) 2015-01-28
EP2832733B1 (en) 2018-08-29
WO2013147215A1 (ja) 2013-10-03
US9212170B2 (en) 2015-12-15
EP2832733A1 (en) 2015-02-04
CA2869130A1 (en) 2013-10-03
ES2699404T3 (es) 2019-02-11
JPWO2013147215A1 (ja) 2015-12-14

Similar Documents

Publication Publication Date Title
ES2883285T3 (es) Antagonistas de tlr7/8 y sus usos
JP6348891B2 (ja) Ｃｘｃｒ４受容体アンタゴニスト
EP2592933B1 (en) Mif inhibitors and their uses
CA3139526A1 (en) Triaryl compounds for treatment of pd-l1 diseases
IL263752A (en) Training modulating compounds
JPWO2010058846A1 (ja) ４，６−ジアミノニコチンアミド化合物
EP2696682A2 (en) Mif inhibitors and their uses
WO2021107023A1 (ja) シクロアルキルウレア誘導体
CN104844566B (zh) 一种新型结构的激酶抑制剂
TW200404060A (en) Fused heterocyclic compounds
KR20160120797A (ko) Mgat2 억제제로서의 아릴 디히드로피리디논 및 피페리디논
CN106220608A (zh) 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
KR20150082616A (ko) 디히드로피라졸 gpr40 조절제
BR112016019487B1 (pt) Inibidores de di-hidropiridinona mgat2 tetrazolonasubstituídos, composição farmacêutica e seus usos
KR20230043885A (ko) 트리시클릭 헤테로사이클
CZ20023243A3 (cs) Pyrrolidinové deriváty, způsob jejich výroby, jejich pouľití a farmaceutický prostředek
JP2025081626A (ja) ペンタミジンの類似体及びその使用
JP6100755B2 (ja) （２−ヘテロアリールアミノ）コハク酸誘導体
JP6126078B2 (ja) ４−アルカノイルアミノ−３−ピラゾロン誘導体
WO2022171072A1 (zh) 一种二氢嘧啶类化合物、其制备方法及其应用
WO2002074743A1 (fr) Compose alicyclique a substitution aryle et composition medicale contenant ce compose
JP7144863B2 (ja) イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
WO2022121844A1 (zh) 一种二氢嘧啶类化合物、其制备方法及应用
CN115124511B (zh) 他克林衍生物及其制备方法与作为cdk2/9抑制剂的应用
KR20240066906A (ko) 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170406

R150 Certificate of patent or registration of utility model

Ref document number: 6126078

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150